Pregabalin controlled-release - Yuhan

Drug Profile

Pregabalin controlled-release - Yuhan

Alternative Names: Pregabalin SR; YHD 1119

Latest Information Update: 05 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yuhan
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neuropathic pain
  • Phase I Neurological disorders

Most Recent Events

  • 10 May 2017 Yuhan Corporation initiates enrolment in a phase I trial for Neuropathic Pain (In volunteers) in South Korea (NCT03191136)
  • 06 Dec 2016 Yuhan Corporation plans a phase III trial for Neuropathic pain in South Korea (PO) (NCT02985216)
  • 01 Dec 2016 Investigation in Neuropathic pain in South Korea (PO) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top